查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592120

白血病药物市场：按类型、按治疗类型、按分子类型、按剂型、按性别 - 2025-2030 年全球预测

Leukemia Therapeutics Market by Type, Treatment Type, Molecule Type, Mode of Administration, Gender - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年白血病药物市值为156.4亿美元，预计到2024年将达到167.3亿美元，复合年增长率为7.02%，到2030年将达到251.7亿美元。

白血病药物的范围包括旨在管理和潜在治癒各种类型白血病的医疗干预和治疗，包括急性淋巴细胞白血病、急性骨髓性白血病、慢性淋巴性白血病和慢性骨髓性白血病的治疗。这些治疗方法包括化疗、免疫疗法、标靶治疗和骨髓移植。全球白血病的高负担以及对有效治疗方案的需求以改善患者的治疗结果和存活率推动了对白血病药物的需求。该调查针对广泛的研究机构、医疗机构和製药公司，重点关注肿瘤学专业人士、研究人员和患者。最终用途范围包括实施这些治疗的医院、癌症研究机构和专科诊所。根据市场洞察，关键的成长要素包括个人化医疗和标靶治疗的进步、研究经费的增加以及全球盛行率的提高。 CAR T 细胞疗法和其他创新免疫疗法的出现代表着一个重大机会，因为它们有望提供更精确、更有效的治疗选择。低毒性、高标靶性的小分子抑制剂的开发也有很大潜力，使我们在市场竞争中具有优势。然而，限制因素包括高昂的治疗成本、复杂的监管核准以及与目前治疗相关的潜在副作用，这些都限制了市场的成长。此外，白血病诊断，特别是在早期阶段，提出了独特的挑战，这进一步使市场扩张变得复杂。创新和研究的最佳领域包括探索药物开发的新机制目标、增强现有治疗的传递机制以及完善基因和生物标记分析以个性化治疗通讯协定。市场具有创新快、竞争激烈的特点，需要相关人员不断创新和合作才能保持竞争力。市场上的成功参与者应专注于与研究机构的合作、研发投资以及适应性策略，以应对可持续成长的监管挑战。

主要市场统计
基准年[2023] 156.4亿美元
预测年份 [2024] 167.3亿美元
预测年份 [2030] 251.7亿美元
复合年增长率（%） 7.02%

市场动态：揭示快速发展的白血病药物市场的关键市场洞察

供需的动态交互作用正在改变白血病药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 白血病患者增加
    • 癌症治疗的需求不断增长
    • 加大医疗健康领域投资
  • 市场限制因素
    • 治疗成本上升和新治疗药物的开发
  • 市场机会
    • 为白血病患者开发创新的诊断和治疗药物
    • 增加对医疗保健产业的投资和有利的政府倡议
  • 市场挑战
    • 严格监管场景

波特五力：驾驭白血病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对白血病药物市场的影响

外部宏观环境因素在塑造白血病药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解白血病治疗药物市场的竞争状况

白血病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵白血病药物市场供应商的绩效评估

FPNV 定位矩阵是评估白血病药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製白血病药物市场的成功之路

白血病药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 白血病发生率上升
      • 癌症治疗的需求不断增加
      • 加大医疗健康领域投入
    • 抑制因素
      • 治疗成本上升和新治疗方法的开发
    • 机会
      • 为白血病患者开发创新的诊断和治疗方法
      • 增加对医疗保健产业的投资和有利的政府倡议
    • 任务
      • 严格监管场景
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章白血病药物市场：按类型

  • 急性淋巴性白血病
  • 急性骨髓性白血病
  • 慢性淋巴性白血病
  • 慢性骨髓性白血病

第七章依治疗类型分類的白血病治疗药物市场

  • 化疗
  • 标靶药物和免疫治疗

第八章按分子类型分類的白血病药物市场

  • 生物製药
  • 小分子

第九章 依管理方式分類的白血病治疗药物市场

  • 注射方式
  • 口语模式

第10章白血病治疗药物市场性别

  • 女士
  • 男人

第十一章 北美、南美白血病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区白血病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲白血病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corp
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4342CA3265BE

The Leukemia Therapeutics Market was valued at USD 15.64 billion in 2023, expected to reach USD 16.73 billion in 2024, and is projected to grow at a CAGR of 7.02%, to USD 25.17 billion by 2030.

The scope of leukemia therapeutics encompasses the range of medical interventions and treatments aimed at managing and potentially curing various types of leukemia, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. These therapies include chemotherapy, immunotherapy, targeted therapy, and bone marrow transplants. The necessity of leukemia therapeutics arises from the high global burden of leukemia, which necessitates effective therapeutic options to improve patient outcomes and survival rates. Applications are broad, involving research laboratories, healthcare institutions, and pharmaceutical companies, catering primarily to oncology specialists, researchers, and patients. End-use scopes include hospitals, cancer research institutes, and specialty clinics that administer these therapies. Market insights reveal that key growth factors include advancements in personalized medicine and targeted therapies, rising research funding, and increasing prevalence rates worldwide. A significant opportunity arises with the advent of CAR T-cell therapies and other innovative immunotherapies that promise more precise and effective treatment options. There is also significant potential in developing less toxic and more targeted small molecule inhibitors, which can provide competitive market advantages. However, limitations include the high cost of treatment, complex regulatory approvals, and potential side effects associated with current therapies, which restrain market growth. Moreover, the inherent challenges in diagnosing leukemia, particularly in its early stages, further complicate market expansion. The best areas for innovation and research include exploring new mechanistic targets for drug development, enhancing delivery mechanisms for existing treatments, and refining genetic and biomarker profiling to personalize therapy protocols. The market is characterized by rapid technological advancements and high competition, necessitating continuous innovation and collaboration among stakeholders to maintain a competitive edge. Successful market players should focus on collaborative efforts with research institutions, investment in R&D, and adaptive strategies to address regulatory challenges for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 15.64 billion
Estimated Year [2024] USD 16.73 billion
Forecast Year [2030] USD 25.17 billion
CAGR (%) 7.02%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Leukemia Therapeutics Market

The Leukemia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of leukemia cases
    • Growing need for cancer therapy
    • Increasing investment in healthcare sector
  • Market Restraints
    • High cost of treatment and development of new therapeutics
  • Market Opportunities
    • Development of innovative diagnostic and therapeutics for leukemia patients
    • Expanding investments in the healthcare sector and favorable government initiatives
  • Market Challenges
    • Stringent regulatory scenario

Porter's Five Forces: A Strategic Tool for Navigating the Leukemia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Leukemia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Leukemia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Leukemia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Leukemia Therapeutics Market

A detailed market share analysis in the Leukemia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Leukemia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Leukemia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Leukemia Therapeutics Market

A strategic analysis of the Leukemia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Biogen Inc, Bristol Myers Squibb Company, Eisai Co., Ltd, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corp, Johnson & Johnson Services, Inc., Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia.
  • Based on Treatment Type, market is studied across Chemotherapy and Targeted Drugs & Immunotherapy.
  • Based on Molecule Type, market is studied across Biologics and Small Molecules.
  • Based on Mode of Administration, market is studied across Injectable Mode and Oral Mode.
  • Based on Gender, market is studied across Female and Male.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of leukemia cases
      • 5.1.1.2. Growing need for cancer therapy
      • 5.1.1.3. Increasing investment in healthcare sector
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and development of new therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of innovative diagnostic and therapeutics for leukemia patients
      • 5.1.3.2. Expanding investments in the healthcare sector and favorable government initiatives
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory scenario
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Leukemia Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Acute Lymphocytic Leukemia
  • 6.3. Acute Myeloid Leukemia
  • 6.4. Chronic Lymphocytic Leukemia
  • 6.5. Chronic Myeloid Leukemia

7. Leukemia Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Targeted Drugs & Immunotherapy

8. Leukemia Therapeutics Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Small Molecules

9. Leukemia Therapeutics Market, by Mode of Administration

  • 9.1. Introduction
  • 9.2. Injectable Mode
  • 9.3. Oral Mode

10. Leukemia Therapeutics Market, by Gender

  • 10.1. Introduction
  • 10.2. Female
  • 10.3. Male

11. Americas Leukemia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Leukemia Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Leukemia Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Biogen Inc
  • 4. Bristol Myers Squibb Company
  • 5. Eisai Co., Ltd
  • 6. F. Hoffmann-La Roche AG
  • 7. Gilead Sciences, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. Incyte Corp
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck KGaA
  • 12. Novartis International AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LEUKEMIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED DRUGS & IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MODE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL MODE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 233. LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023